BackCodex DNA Overview

Codex DNA Receivables

Codex DNA's receivables is $1.3M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$1.26M
↓ 76.45% YoYΔ $-4.10M vs prior year quarter

Peer trimmed avg / median

Loading

Codex DNA Receivables History

Loading

Codex DNA vs. peers: Receivables Comparison

Loading

Codex DNA Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Codex DNA (DNAY) FAQ

As of the most recent data (September 2024), DNAY shows a receivables of $1.3M. That compares with $5.4M in the prior-year period — down 76.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, DNAY's receivables is now $1.3M (was $5.4M) — a 76.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Codex DNA is outperforming or lagging.

Tracking DNAY's receivables over time shows whether Codex DNA is scaling, shrinking, or reshaping that part of the business. The current reading is $1.3M That compares with $5.4M in the prior-year period — down 76.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Codex DNA's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $1.3M) with ownership activity and broader fundamentals.

Codex DNA's receivables is $1.3M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.